NCT07940140
Gut Barrier Function and Metabolic Risk in Women With Excessive Gestational Weight Gain
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Serum Zonulin Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum I-FABP Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum GLP-2 Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum LBP Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum sCD14 Level
Timeframe: At enrollment (≥37 weeks of gestation)
Secondary (8)
Serum TNF-alpha Level
Serum IL-6 Level
Serum hs-CRP Level
Serum Vitamin D Receptor Level
Serum 25-Hydroxyvitamin D Level
Show 3 moreShow less
Fasting Blood Glucose Level
Fasting Serum Insulin Level
HOMA-IR Index
Arms and interventions
Excessive Gestational Weight Gain Group
Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain exceeding the 2009 IOM recommendations (n=40).
Recommended Gestational Weight Gain Group (Control Group)
Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain within the 2009 IOM recommended range (n=40).
Sites
1 site in 1 country
- Sivas Cumhuriyet University Faculty of Medicine HospitalSivas, Sivas, Turkey (Türkiye)